2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N12102
    Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside
    		Inhibitor
    Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside (compound 1) is a lignan with anti-HBC activity. Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside targets HBV surface antigen with IC50s of 0.58 mM (HBsAg) and >2.4 mM (HBeAg). Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside can be isolated from star anise.
    Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside
  • HY-145060
    HBV-IN-13
    		Inhibitor
    HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor. From patent WO2021204252A1, compound 1_B.
    HBV-IN-13
  • HY-P990421
    Anti-GOLM1 Antibody
    Anti-GOLM1 Antibody is a CHO-expressed human antibody that targets GOLM1. The Anti-GOLM1 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GOLM1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-GOLM1 Antibody
  • HY-P4050
    HBV Seq1 aa:18-27
    HBV Seq1 aa:18-27 is a hepatitis B virus (HBV) core antigen 18-27 peptide fragment.
    HBV Seq1 aa:18-27
  • HY-148151
    (-)-5′-Noraristeromycin
    		Inhibitor
    (-)-5′-Noraristeromycin is an antiviral agent. (-)-5′-Noraristeromycin also is an enantiomer of 5'-noraristeromycin and can inhibit intracellular HBV replication and virion production. (-)-5′-Noraristeromycin can be used for the research of cancer.
    (-)-5′-Noraristeromycin
  • HY-155968
    HBV-IN-40
    		Inhibitor
    HBV-IN-40 (Compound 11826096) is a HBV inhibitor (IC50: 0.7 μM). HBV-IN-40 is an antiviral agent.
    HBV-IN-40
  • HY-163516
    HBV-IN-45
    		Inhibitor
    HBV-IN-45 is a selective and orally active HBV capsid assembly modulator with an IC50 of 0.51 μM for HBcAg in HBC cells. HBV-IN-45 shows potent anti-HBV activities.
    HBV-IN-45
  • HY-163581A
    HBV/HDV-IN-4 hydrochloride
    		Inhibitor
    HBV/HDV-IN-4 hydrochloride (Compd 4) is a dual HBV and HDV inhibitor, with an EC50 of <50 nM against HBV.
    HBV/HDV-IN-4 hydrochloride
  • HY-161604
    HBV/HDV-IN-1
    		Inhibitor
    HBV/HDV-IN-1 (Compd 122) is a HBV, HDV and PD-1/PD-L1 inhibitor, with EC50 values of 8 nM for T cell activation and 35 nM for PD-L1 internalization.
    HBV/HDV-IN-1
  • HY-P4051
    HBV Seq1 aa:141-151
    HBV Seq1 aa:141-151 is a peptide. HBV Seq1 aa:141-151 can be used for the research of chronic hepatitis B virus (HBV) .
    HBV Seq1 aa:141-151
  • HY-163149
    AB-452
    		Inhibitor
    AB-452, a Dihydroquinolizinone (DHQ) analogue, is a potent and orally active HBV RNA destabilizer. AB-452 inhibits PAPD5/7 proteins in vitro with good in vivo efficacy in a chronic HBV mouse model.
    AB-452
  • HY-N0056R
    Isochlorogenic acid A (Standard)
    		Inhibitor
    Isochlorogenic acid A (Standard) is the analytical standard of Isochlorogenic acid A. This product is intended for research and analytical applications. Isochlorogenic acid A (3,5-Dicaffeoylquinic acid) is a natural phenolic acid with anti-mutagenicity, anti-HBV, anti-HIV, anti-oxidant, anti-bacterial, and anti-inflammatoryy activities.
    Isochlorogenic acid A (Standard)
  • HY-N2882
    Apigenin-4'-α-L-rhamnoside
    		Inhibitor
    Apigenin-4'-α-L-rhamnoside is a potent inhibitor of HBV. Apigenin-4'-α-L-rhamnoside inhibits the secretory level of HBV surface antigen (HBsAg) in HepG2.2.15 cells.
    Apigenin-4'-α-L-rhamnoside
  • HY-172835
    Rapavir
    		Inhibitor
    Rapavir (JH-B10) is a selective and potent sodium taurocholate cotransporting polypeptide (NTCP) inhibitor with an IC50 value of 1.8 nM for the uptake of taurocholic acid-d4 (TCA-d4). Rapavir exerts antiviral activity by directly binding to NTCP and blocking the entry of the virus into cells during the HBV infection phase. Rapavir is promising for research of HBV infections.
    Rapavir
  • HY-149435
    HBV-IN-36
    		Inhibitor
    HBV-IN-36 (compound 42) is a HBV inhibior (IC50=2 μM), showing anti-HBV activity with EC50 of 0.58 μM.
    HBV-IN-36
  • HY-148201
    Oleana-2,12-dien-28-oic acid
    		Inhibitor 99.88%
    Oleana-2,12-dien-28-oic acid is an HBV-DNA inhibitor, HBsAg and HBeAg inhibitor. Oleana-2,12-dien-28-oic acid can be used in hepatitis B virus infection disease research.
    Oleana-2,12-dien-28-oic acid
  • HY-144045
    HBV-IN-14
    		Inhibitor
    HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection (extracted from patent WO2021190502A1, compound 5).
    HBV-IN-14
  • HY-116001B
    (-)-Carbovir
    		Inhibitor
    (-)-Carbovir is an active compound.
    (-)-Carbovir
  • HY-111073
    Bentysrepinine
    		Inhibitor
    Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields.
    Bentysrepinine
  • HY-145059
    HBV-IN-12
    		Inhibitor
    HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μM＜EC50 ≤0.02 μM). From patent WO2021204252A1, compound 15.
    HBV-IN-12
Cat. No. Product Name / Synonyms Application Reactivity